Article
Biochemistry & Molecular Biology
Ciara Murphy, Gloria Gornes Pons, Anna Keogh, Lisa Ryan, Lorraine Mccarra, Chris Maria Jose, Shagun Kesar, Siobhan Nicholson, Gerard J. Fitzmaurice, Ronan Ryan, Vincent Young, Sinead Cuffe, Stephen P. Finn, Steven G. Gray
Summary: This study investigated the expression and potential clinical utility of JADE2 in non-small cell lung cancer (NSCLC). The results showed that JADE2 expression is significantly altered in NSCLC and high expression of JADE2 is associated with better overall survival. The study also identified associations between JADE2 expression and tumor mutational burden and immune cell infiltration, as well as potential new drugs targeting JADE2. Overall, JADE2 may have potential diagnostic, prognostic, and therapeutic implications in NSCLC.
Article
Biology
Zahra Khodabakhshi, Shayan Mostafaei, Hossein Arabi, Mehrdad Oveisi, Isaac Shiri, Habib Zaidi
Summary: This study aimed to identify important features for classifying NSCLC subtypes using CT radiomics, with a focus on the gray level size zone matrix features (GLSZM). Results showed that these texture features were significant indicators for distinguishing between NSCLC subtypes, leading to an optimized classifier with high precision, recall, F1-score, and accuracy. This demonstrates the potential of CT radiomics in precision medicine and treatment planning for NSCLC patients.
COMPUTERS IN BIOLOGY AND MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Shane P. Smith, Adam J. Bograd, Gal Levy, Shu-Ching Chang, Alex S. Farivar, Ralph W. Aye, Brian E. Louie, Eric Vallieres
Summary: This study investigated the impact of resection extent on overall survival and recurrence patterns in lung cancer patients with tumors invading across the fissure. Results showed that parenchymal-sparing resections can reduce immediate surgical morbidity, do not increase the cumulative incidence of recurrence, and have no significant difference in overall survival compared to maximal resections.
ANNALS OF THORACIC SURGERY
(2021)
Review
Biochemistry & Molecular Biology
Aaron C. Tan, Nick Pavlakis
Summary: The management of advanced lung cancer has been transformed by the identification of targetable oncogenic driver alterations, including ALK gene rearrangements. ALK tyrosine kinase inhibitors have become the first-line treatment options for advanced ALK rearranged NSCLC. However, drug resistance remains a challenge, and the role of anti-angiogenic therapy in ALK rearranged NSCLC needs further exploration.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Immunology
Li-Chung Chiu, Shu-Min Lin, Yu-Lun Lo, Scott Chih-Hsi Kuo, Cheng-Ta Yang, Ping-Chih Hsu
Summary: Early-stage NSCLC patients face high risks of recurrence and death even after surgery, with limited improvements from traditional treatments like chemotherapy and radiation. Immunotherapies, including immune checkpoint inhibitors and cancer vaccination, have shown potential in improving survival rates and are being actively researched in clinical trials.
Article
Radiology, Nuclear Medicine & Medical Imaging
Hyewon Choi, Young Sik Park, Kwon Joong Na, Samina Park, In Kyu Park, Chang Hyun Kang, Young Tae Kim, Jin Mo Goo, Soon Ho Yoon
Summary: This study investigated the association between baseline adipopenia and outcomes in patients with early-stage NSCLC. The results showed that adipopenia was associated with a reduced 5-year overall survival rate, indicating a potential risk for non-cancer-related death.
Review
Biochemistry & Molecular Biology
Calogera Claudia Spagnolo, Giuliana Ciappina, Elisa Giovannetti, Andrea Squeri, Barbara Granata, Chiara Lazzari, Giulia Pretelli, Giulia Pasello, Mariacarmela Santarpia
Summary: In recent years, the development of therapeutic agents targeting actionable oncogenic drivers in metastatic non-small cell lung cancer (NSCLC) has increased. Selective inhibitors, such as tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, have shown promising results in patients with MET deregulation, specifically exon 14 skipping mutations or MET amplification. This review provides an overview of MET signaling pathways, oncogenic alterations, laboratory techniques for detection, clinical data and ongoing studies on MET inhibitors, resistance mechanisms, and potential strategies for improving outcomes in MET-exon 14-altered NSCLC patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Pharmacology & Pharmacy
Chetna Gupta, Aadya Jaipuria, Nikesh Gupta
Summary: Cancer, particularly lung cancer, is a major cause of mortality. The current primary methods of treatment for lung cancer include oral and systemic drug administration, radiotherapy, and chemotherapy. However, these methods have limitations such as adverse effects, toxicity, and resistance. To overcome these challenges, pulmonary drug delivery systems have been developed, allowing localized delivery of drugs to cancer cells and reducing systemic toxicities. Nano-based systems also provide additional diagnostic advantages. However, pulmonary delivery is still in the early stages of development and various factors need to be considered for the development of suitable inhalable nano-based chemotherapeutic drugs. This review article focuses on inhalable formulations for targeted drug delivery and discusses various devices used in pulmonary drug delivery.
Article
Pharmacology & Pharmacy
Suyash M. Patil, Shruti S. Sawant, Nitesh K. Kunda
Summary: This study developed inhalable BQ-loaded cubosome nanocarriers for NSCLC treatment, showing enhanced therapeutic effects and aerosolization performance compared to free BQ.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2021)
Review
Health Care Sciences & Services
Maja Sutic, Ana Vukic, Jurica Baranasic, Asta Foersti, Feda Dzubur, Miroslav Samarzija, Marko Jakopovic, Luka Brcic, Jelena Knezevic
Summary: Lung cancer is the leading cause of cancer-related deaths globally, with most patients still being diagnosed at an advanced stage despite screening efforts for high-risk populations. In the past decade, management of lung cancer has significantly progressed towards personalized treatments, with molecular biomarkers playing a crucial role in prognosis and predicting therapy response. Non-small cell lung cancer, being the most common type, is the primary focus for discussion on promising new biomarkers in clinical management.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Oncology
Mariya Tikhomirova, Iuliia Topchu, Aleksandra Mazitova, Vitaly Barmin, Ekaterina Ratner, Alexey Sabirov, Zinaida Abramova, Alexander Y. Deneka
Summary: This study reveals a novel role for the scaffolding protein NEDD9 in regulating DNA damage response signaling and sensitivity to DNA damaging therapies in lung cancer. Experimental results demonstrate that NEDD9 depletion enhances ATM-CHK2 signaling, leading to cellular phenotype transition and increased sensitivity to UV irradiation. Furthermore, immunohistochemical analysis finds an association between reduced NEDD9 protein expression and decreased overall survival of lung cancer patients.
Review
Pathology
Firoozeh Abolhasani Zadeh, Ahmed Raji, Sana Abdul-Jabbar Ali, Walid Kamal Abdelbasset, Natalia Alekhina, A. Heri Iswanto, Ermias Mergia Terefe, Abduladheem Turki Jalil
Summary: This study provides an overview of the complexity of autophagy in response to chemoradiotherapy in lung cancer. It highlights the dual role of autophagy in both sensitizing cancer cells to therapy and promoting their survival.
PATHOLOGY RESEARCH AND PRACTICE
(2022)
Review
Radiology, Nuclear Medicine & Medical Imaging
Sara E. Dahlsgaard-Wallenius, Malene Grubbe Hildebrandt, Allan Johansen, Mie Holm Vilstrup, Henrik Petersen, Oke Gerke, Poul Flemming Hoilund-Carlsen, Anni Morsing, Thomas Lund Andersen
Summary: PET/MRI did not show advantages in T- and N-staging for NSCLC compared to PET/CT. The detection rate of FDG-avid lung nodules larger than 10mm with PET/MRI was comparable to that of PET/CT, but the sensitivity for non-FDG-avid nodules smaller than 5mm was low. Overall, PET/MRI had a lower detection rate for lung nodules in various cancer types compared to PET/CT due to the lower diagnostic performance of MRI in the lungs.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Review
Pharmacology & Pharmacy
Stefanie Ho Yi Chan, Yasmin Khatib, Sherael Webley, Deborah Layton, Sam Salek
Summary: In the last few decades, cancer therapies and detection strategies have rapidly developed, resulting in decreased cancer-related death rates. However, cardiovascular disease has emerged as the second leading cause of morbidity and mortality among cancer survivors. Cardiotoxicity from anticancer drugs can affect the heart's function and structure, leading to the development of cardiovascular disease.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Xueru Zhu, Yiting Wang, Chang Jiang, Xiaoyang Li, Linying Sun, Guangzhong Wang, Xiaolong Fu
Summary: This study explored the intrinsic radiosensitivity of non-small cell lung cancer (NSCLC) and identified radiosensitivity-specific proteins that can guide individualized radiation therapy. The study also validated the functions of these proteins in NSCLC cell lines and delineated the atlas network of NSCLC radiosensitivity-related signaling pathways, which could further contribute to the understanding of the underlying mechanism.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)